Tenpoint Therapeutics, Ltd

This page is intended for US audiences only. Tenpoint Therapeutics Limited is a commercial-ready biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye. Its pipeline includes paradigm-shifting treatments for ophthalmic indications with the greatest need and global market potential, including presbyopia, cataracts, and geographic atrophy. Its lead asset, BRIMOCHOL PF, is a novel, pupil-modulating investigational therapeutic designed to correct the loss of near vision associated with presbyopia, a condition that impacts nearly 128 million people in the U.S. Tenpoint Therapeutics has completed two large Phase 3 pivotal trials (BRIO-I and BRIO-II) for BRIMOCHOL PF, has filed the NDA and has received a Prescription Drug User Fee Act (PDUFA) date from the US FDA of January 28, 2026. Tenpoint Therapeutics’ leadership team includes ophthalmic industry luminaries with track records of successful approvals and commercialization of blockbuster treatments.